Výsledky vyhledávání - "G.M. Bohns Meyer"

Long-Term Efficacy of Oral Treprostinil in Subjects with Pulmonary Arterial Hypertension: FREEDOM-EV Open-Label Extension Study

Autor: R.J. White, M. Broderick, C.Q. Deng, R. Grover, L. Holdstock, A. Khan, G.M. Bohns Meyer, B. Ng, T. Pulido Zamudio, I. Saib, P. Sepulveda

Publikováno v: A96. GIANTS STADIUM: TREATMENTS AND TRIALS IN PULMONARY HYPERTENSION.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35ce1979ec518de33caca73ee8f64ca4
https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2152

Zobrazit plný text záznamu

PULSAR Open-Label Extension: Long-Term Efficacy and Safety of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

Autor: M. Humbert, V.V. Mclaughlin, S.R. Gibbs, M. Gomberg-Maitland, M. Hoeper, I.R. Preston, R. Souza, A.B. Waxman, H.A. Ghofrani, P. Escribano Subias, J.P. Feldman, G.M. Bohns Meyer, D. Montani, K.M. Olsson, S. Manimaran, J. de Oliveira Pena, D.B. Badesch

Publikováno v: A96. GIANTS STADIUM: TREATMENTS AND TRIALS IN PULMONARY HYPERTENSION.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f537449625aa3b2e4e23e51cb216f23
https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2150

Zobrazit plný text záznamu

Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE Study

Autor: G.M. Bohns Meyer, H. Al Hiti, E. Grünig, M. Hoeper, D. Langleben, T. Pulido, S. Rosenkranz, G. Simonneau, R.J. White, C. Rahner, C. Meier, S. Bansilal, H.-A. Ghofrani

Publikováno v: D3. D003 COME TOGETHER - CLINICAL ADVANCES IN PULMONARY HYPERTENSION: LESSONS FROM BEST ABSTRACTS.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::81ec8f314f18129d76722e33476e098c
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1184

Zobrazit plný text záznamu

Risk Scores and Risk-Based Stratification of Clinical Worsening Events in Pulmonary Arterial Hypertension Participants Treated with Oral Treprostinil: FREEDOM-EV

Autor: R.J. White, C. Jerjes-Sanchez, G.M. Bohns Meyer, T. Pulido, P. Sepulveda, K.Y. Wang, C.Q. Deng, R. Grover, V.F. Tapson, null on behalf of FREEDOM-EV investigato

Publikováno v: C97. DON'T STOP BELIEVING: CLINICAL TRIALS IN PULMONARY VASCULAR MEDICINE.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::08d4246d5f80cf525963da27aca6e2bd
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5587

Zobrazit plný text záznamu

Treatment with Oral Treprostinil Delays Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension - Results from FREEDOM-EV

Autor: Tomás Pulido, R. Grover, R.J. White, P. Sepulveda, C.Q. Deng, G.M. Bohns Meyer, D. Solum, C.J. Sanchez Diaz, A. Ousmanou, Victor F. Tapson, K.Y. Wang

Publikováno v: The Journal of Heart and Lung Transplantation. 38:S94-S95

Purpose Oral treprostinil (TRE) has been shown to improve exercise capacity in patients with pulmonary arterial hypertension (PAH), but its effect on clinical outcomes was unknown. Methods In this global, event-driven study, eligible participants tak

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f432fe1c1d107c5a0bb252352ad27a24
https://doi.org/10.1016/j.healun.2019.01.220

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání